CA-NEXTROLL
10.9.2019 16:02:03 CEST | Business Wire | Press release
AdRoll Group today announced it has rebranded as NextRoll, Inc. , a marketing and data technology company. Additionally, NextRoll is introducing external APIs to open its infrastructure, technology and data to a wide array of new companies. NextRoll is now comprised of three business units: RollWorks , an account-based platform for B2B marketing and sales teams; AdRoll , a growth marketing platform for direct-to-consumer (DTC) brands; and NextRoll Platform Services , a marketing-technology-as-a-service offering for brands, agencies, marketplaces, publishers, and marketing platforms to enhance current marketing capabilities or enable new revenue streams.
As online marketing has become more complex, many companies must choose between building their own technology stacks or working with closed-system providers, which can result in losing control, flexibility and customer insight. Now, with NextRoll Platform Services, companies can access leading marketing technology, data and channels without sacrificing relationships with their key audiences. For example, marketplaces can improve demand generation by giving their customers access to premium tools and audiences from NextRoll.
NextRoll Platform Services leverages rich data assets for unified, people-based profiles across first-, second- and third-party data, including more than 500 million identities and 1 billion devices. Additionally, NextRoll’s machine-learning capabilities enable companies to provide marketing messages, activate curated audiences and measure which efforts drive the greatest impact. NextRoll Platform Services customers can scale as needed, with a global infrastructure that covers 110 countries and manages up to five petabytes of stored data and 12 trillion real-time events processed daily.
“We’ve built an unrivaled marketing and data technology stack that enables marketers to better understand and engage with their audiences to make measurable decisions,” said Toby Gabriner, CEO of NextRoll. “With our new NextRoll Platform Services, we can offer these benefits to more companies, and allow them to innovate on top of our offerings. As we launch NextRoll Platform Services, it’s clear we’ve grown beyond our old name. Today, NextRoll is a marketing and data technology company.”
Services available today include:
Channels-as-a-Service
Channels-as-a-Service from NextRoll Platform Services allows businesses to expand their marketing solutions to new channels, including display ads, social media, native ads, email and video across devices enabling their customers to attract and re-engage audiences. With integrations to over 20 publishers and exchanges from Channels-as-a-Service, users can access the best inventory at any time to accelerate budget fulfillment and hit performance goals. They also gain granular insights into conversion, audience, performance and delivery data.
Audiences-as-a-Service
Many companies end up with vast amounts of raw audience data that is difficult to comprehend. With Audiences-as-a-Service from NextRoll Platform Services, companies have a unified and normalized view across identities and platforms within their existing data set, turning data into targetable segments they can ingest at scale and use in real-time. With this view, companies can better understand and serve each customer or segment. Companies can also enrich internal user profiles by leveraging the NextRoll database or package up these audience insights into premium, targetable segments for resale.
NextRoll Platform Services currently has 10 large customers that drive nearly $1 million in revenue per month, and has significant traction in the pipeline. A key contributor to the momentum is an existing joint venture with Rakuten in the Japanese market that leverages NextRoll Platform Services.
NextRoll Platform Services will release additional offerings in 2020 and beyond. Developers can access integration toolkits here .
About NextRoll
NextRoll, Inc. is a marketing and data technology company on a mission to accelerate growth for companies, big and small. Since 2007, our technology has powered a suite of data-driven marketing solutions and services. NextRoll Platform Services offer marketing-technology-as-a-service for brands, agencies, marketplaces, publishers and marketing platforms, to create more value for their business. Ambitious DTC brands use AdRoll products to make their display, social, and email advertising work together to accelerate business growth. RollWorks offers ambitious B2B companies an account-based platform to align their marketing and sales teams and confidently grow revenue. NextRoll empowers over 37,000 customers worldwide to understand, attract and engage buyers, driving growth for their businesses.
NextRoll is a privately-held company headquartered in San Francisco, CA. Company products honor the best practices for data use and privacy of leading associations including the Network Advertising Initiative (NAI) and the Digital Advertising Alliance’s (DAA) App Choices programs. Learn more about NextRoll at nextroll.com
AdRoll, NextRoll and RollWorks are trademarks NextRoll.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005355/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom